The predictive value of systemic immune-inflammation index for immune checkpoint inhibitor treatment-related adverse reactions in patients with primary liver cancer
Objective To investigate the predictive value of systemic immune-inflammation index(SII)for the treat-ment-related adverse reactions of immune checkpoint inhibitors(ICIs)in patients with primary liver cancer(PLC).Methods A total of 162 patients with PLC who received ICIs treatment from January 2022 to October 2023 were se-lected and divided into immune-related adverse events(irAEs)group and non-irAEs group according to whether irAEs occurred.The clinical data of the two groups were collected and compared.Multivariate Logistic regression analysis was used to analyze the influencing factors of irAEs in the PLC patients treated with ICIs.The receiver operating characteris-tic(ROC)curve was drawn to evaluate the predictive value of SII for irAEs in the PLC patients after ICIs treatment.Results Among the 162 PLC patients treated with ICIs,there were 77 cases of irAEs,accounting for 47.53%,of which 74 cases were single irAEs,and endocrine toxicity was the most common(13.58%).There were 3 cases of mul-tiple irAEs,and hepatotoxicity combined with skin toxicity was the most common(1.23%).Multivariate Logistic re-gression analysis showed that previous history of autoimmune diseases,IL-6 and SII were independent risk factors for irAEs in PLC patients treated with ICIs(P<0.05).The results of ROC curve analysis showed that the area under the curve of IL-6 and SII in predicting irAEs in PLC patients treated with ICIs was 0.693(95%CI:0.589-0.797)and 0.816(95%CI:0.732-0.900),respectively.The optimal cutoff value of SII was 1336.8×109/L,and the sensitivity was 87.76%and the specificity was 63.65%.Conclusion SII has a good value in predicting irAEs in PLC patients treated with ICIs,and is an independent risk factor.
NETL
NSTL
万方数据
